Trial Profile
An open label single arm phase-I study to evaluate safety, reactogenicity and immunogenicity of single intramuscular dose of Biological E's Vi-capsular Polysaccharide-CRM197 Conjugate Typhoid Vaccine in 18-45 year-old healthy adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary)
- Indications Typhoid
- Focus Adverse reactions; First in man
- Sponsors Biological E Limited
- 10 Jan 2020 Status changed from active, no longer recruiting to completed.
- 26 Jun 2018 New trial record